Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is maintaining its upward momentum in pre-market trading on Friday, surging 5.71% following a spectacular 184% gain on Thursday. The continued rally comes on the heels of the company's announcement of positive results from two pivotal Phase 3 trials for its essential tremor drug, ulixacaltamide.

The clinical-stage biopharmaceutical company reported that both studies met their primary endpoints, demonstrating statistically significant and clinically meaningful improvements in patients' daily functioning and tremor control. This success positions Praxis as a frontrunner in movement disorder drug development, addressing a significant unmet need in the treatment of essential tremor.

Adding to the positive sentiment, Praxis announced the pricing of a $525 million public offering of shares and pre-funded warrants. The company is offering 3,025,480 shares at $157.00 per share, along with pre-funded warrants to purchase up to 318,470 shares. This substantial capital raise is likely to fund the company's efforts to bring ulixacaltamide to market, pending FDA approval.

The market's enthusiasm is further bolstered by analyst upgrades, with TD Cowen raising its price target for Praxis from $61 to $251. This significant increase in valuation reflects growing confidence in the company's potential to capture a multi-billion dollar market opportunity with its breakthrough treatment for essential tremor.